Cogent Biosciences, Inc.

NASDAQ•COGT

CEO: Mr. Andrew R. Robbins M.B.A.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 2018-03-29

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Contact Information

275 Wyman Street, 3rd Floor, Waltham, MA, 02451, United States

617-945-5576

www.cogentbio.com

Market Cap

$6.31B

P/E (TTM)

-8.0

19.5

Dividend Yield

52W High

$43.73

52W Low

$3.72

52W Range

88%

Rank47Top 61.9%

3.4

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Weak • 3.4 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$0.00+0.00%

4-Quarter Trend

EPS

-$0.69+0.00%

4-Quarter Trend

FCF

-$79.92M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Bezuclastinib Clinical Progress Positive top-line results achieved for SM and GIST indications in 2025; NDA submission for NonAdvSM completed.

Financing Activities Strong Financing provided $878.2M in 2025, including $222.8M from Notes issuance, bolstering capital resources.

Cash Position Strong Cash, equivalents, and securities totaled $900.8M as of December 31, 2025, funding operations into 2028.

R&D Spending Increased Research and development expenses rose $37.1M to $269.78M in 2025, supporting clinical trial progression.

Risk Factors

Continued Net Losses Incurred Net loss reached $328.94M in 2025, increasing $73.08M from 2024; operations remain unprofitable.

Pipeline Dependency Risk Business success highly dependent on bezuclastinib program success; pipeline expansion requires substantial funding.

Manufacturing Sole Source Risk API and drug product for bezuclastinib rely on single-source suppliers; loss significantly harms business operations.

Regulatory Approval Uncertainty Regulatory plans may face disagreement from FDA; approval for all indications is not guaranteed.

Outlook

Commercial Launch Planned Expect US commercial launch for NonAdvSM in second half of 2026, pending successful FDA regulatory approval.

Pipeline Advancement Continues Plan to initiate Phase 1 study for ErbB2 inhibitor and submit IND for KRAS/JAK2 programs in 2026.

Future Capital Requirements Expect substantial future expenses; additional financing required to complete development and commercialization efforts.

GIST NDA Submission Target Expect to complete GIST NDA submission in April 2026, following RTOR acceptance in January 2026.

Peer Comparison

Revenue (TTM)

SRPT

$2.20B

+15.6%

GLPG

$1.26B

+303.5%

RCUS

$247.00M

-4.3%

Gross Margin (Latest Quarter)

AGIO

96.9%

-4.3pp

LQDA

94.2%

+29.3pp

RCUS

90.9%

-7.7pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
IBRX	$10.28B	-29.4	64.3%	175.0%
COGT	$6.31B	-8.0	-100.2%	27.0%
DNLI	$3.28B	-7.2	-50.1%	2.9%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

N/M

Revenue Volatile

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:May 4, 2026

EPS:-

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data